Clinical trial NCT06836765: The Relationship Between the Differential Expression of FosB Protein in Laryngeal Cancer Tissues and Clinical Prognosis
Official title: Expression of FosB Gene in Laryngeal Cancer Tissues and It's Clinical Prognosis Significance
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Laryngeal Carcinoma
Keywords: Laryngeal cancer
FosB(FBJ murine osteosarcoma viral oncogene homolog B) gene
Immunohistochemistry
Cox regression analysis
Lead sponsor: Neijiang No.2 People's Hospital
Sponsor class: OTHER
First posted: 2025-02-20
Enrollment: 100
Sex: ALL
Minimum age (years): 35
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Researchers are Collecting 100 to 200 cases of laryngeal cancer patients who have been finally diagnosed and treated in research institution.

Brief summary: To determine whether there is statisstical difference in FosB (FBJ murine osteosarcoma viral oncogene homolog B) protein expression between laryngeal cancer tissue and adjacent tissue through immunohistochemistry methods.

If there are differences, further the investigators will collect relevant patients information,such as clinical stages, pathological types, clinical prognosis and so on. ultimately analyze whether it is related to the expression of FOsB in laryngeal cancer tissue and adjacent tissues

Detailed description: First,the investigators will collect 100 to 200 cases of laryngeal cancer patients who have been finally diagnosed and treated in our institution in the past five years. Laryngeal cancer pathological tissues and adjacent tissues will be selected to make pathological sections. Use immunohistochemistry to confirm the differences in FosB protein between laryngeal cancer tissues and adjacent tissues, and clarify whether there are differences.

secondly,if there are differences, further the investigators will collect relevant patients information,such as clinical stages, pathological types, clinical prognosis and so on. Review the clinical data of corresponding patients, including age, gender, smoking and alcohol history, clinical stages, pathological types and clinical prognosis, etc., and compare whether there are statistical differences.

Finally, clinical prognostic data of relevant patients were collected through outpatient follow-up, online and telephone follow-up, to determine whether there is a correlation between Fosb expression in laryngeal cancer tissue and clinical prognosis.

Eligibility criteria: Inclusion Criteria:

* laryngeal squamous cell carcinoma was diagnosed ,and biopsy was confirmed by two pathologists;
* Primary tumor of Laryngeal ,and there was no distant metastasis;
* Standard treatment such as surgery and Preliminarily-diagnosed parients;
* full clinical and pathological data information and good follow-up;
* there was no previous fatal diseases such as complicated tumors.

Exclusion Criteria:

* Secondary cancer or cancer with distant metastasis;
* Patients who have not seen a doctor for the first time or have received surgery or radiotherapy or chemotherapy in other hospitals;
* Clinical and pathological data were missing and loss to follow-up;
* Patients who abandoned treatment or standard treatment procedures has not been completed;
* The past medical history of other lethal diseases such as complicated tumors.

Primary outcomes:
measure: the number of fosb gene positive expression cases in laryngeal carcinoma cells and adjacent tissues was determined.
timeFrame: one month
Secondary outcomes:
measure: _Experimental result of western blot and PCR._Correlation analysis data between clinical information and experimental results..
timeFrame: three months
Other outcomes:
Locations:
city: Nanchong
country: China
facility: Cllinical Laboratory of Chuanbei Medical College
state: China/SiChuan
Study officials:
References:
citation: Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer. 2003 Nov;3(11):859-68. doi: 10.1038/nrc1209. No abstract available.
citation: Liu S, Luan J, Ding Y. miR-144-3p Targets FosB Proto-oncogene, AP-1 Transcription Factor Subunit (FOSB) to Suppress Proliferation, Migration, and Invasion of PANC-1 Pancreatic Cancer Cells. Oncol Res. 2018 Jun 11;26(5):683-690. doi: 10.3727/096504017X14982585511252. Epub 2017 Jun 24.
citation: Hung YP, Fletcher CD, Hornick JL. FOSB is a Useful Diagnostic Marker for Pseudomyogenic Hemangioendothelioma. Am J Surg Pathol. 2017 May;41(5):596-606. doi: 10.1097/PAS.0000000000000795.